Mird237

If you have ever wondered how doctors determine exactly how much radiation a tumor will receive—or, more critically, how much a healthy organ like the liver or bone marrow will absorb—you have encountered the legacy of MIRD237. This article provides a comprehensive deep dive into what MIRD237 is, why it remains a cornerstone of dosimetry, and how it is evolving in the era of personalized theranostics. MIRD237 is the formal designation for a seminal publication by the Society of Nuclear Medicine (SNM) and the Medical Internal Radiation Dose (MIRD) Committee. Officially titled "MIRD Cellular S Values: Self-Absorbed Dose per Unit Cumulated Activity for Selected Radionuclides and Cellular Models," MIRD237 (often referred to in shorthand as "MIRD Pamphlet No. 23" or the cellular S-value supplement) extended classical organ-level dosimetry into the microscopic domain.

For decades, MIRD pamphlets (No. 1 through No. 22) focused on —standardized geometric representations of the human body. But as therapy moved from diagnostic doses to high-activity treatments (e.g., Y-90 microspheres for liver cancer, Lu-177 DOTATATE for neuroendocrine tumors), clinicians needed cellular and subcellular resolution. mird237

using pharmacokinetic modeling (often a 1- or 2-compartment model). If you have ever wondered how doctors determine